Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Compass Therapeutics (CMPX) Research & Development: 2019-2024

Historic Research & Development for Compass Therapeutics (CMPX) over the last 6 years, with Dec 2024 value amounting to $42.3 million.

  • Compass Therapeutics' Research & Development rose 48.93% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year increase of 32.58%. This contributed to the annual value of $42.3 million for FY2024, which is 11.08% up from last year.
  • As of FY2024, Compass Therapeutics' Research & Development stood at $42.3 million, which was up 11.08% from $38.1 million recorded in FY2023.
  • Compass Therapeutics' 5-year Research & Development high stood at $42.3 million for FY2024, and its period low was $14.9 million during FY2020.
  • Moreover, its 3-year median value for Research & Development was $38.1 million (2023), whereas its average is $36.8 million.
  • Per our database at Business Quant, Compass Therapeutics' Research & Development slumped by 33.61% in 2020 and then skyrocketed by 47.50% in 2022.
  • Over the past 5 years, Compass Therapeutics' Research & Development (Yearly) stood at $14.9 million in 2020, then spiked by 36.45% to $20.3 million in 2021, then skyrocketed by 47.50% to $30.0 million in 2022, then rose by 27.08% to $38.1 million in 2023, then increased by 11.08% to $42.3 million in 2024.